Forane100 ml

Forane is a volatile halogenated general anesthetic gas administered only by inhalation in a hospital/surgical setting, using a calibrated vaporizer, by trained anesthesia personnel.

Established / FDA-Approved Uses

• Induction of general anesthesia in adults and pediatric patients (though a pungent odor and airway irritation limit its use for mask induction, particularly in children, where other agents are often preferred).
• Maintenance of general anesthesia for surgical procedures of varying duration, typically combined with nitrous oxide/oxygen or oxygen alone, and often with adjunct intravenous agents, analgesics, and neuromuscular blocking drugs.

Notes on Evidence and Use

• Adequate and well-controlled data supporting use in obstetric anesthesia (e.g., cesarean section) have not been established; use in this setting requires specialist judgment.
• Forane is not indicated for, and must never be used for, sedation or analgesia outside a monitored anesthesia setting; it is not a self-administered or ward-level medication.

A qualified anesthesiologist or anesthesia provider must determine the appropriateness of Forane for each patient and procedure.

Isoflurane is supplied as a clear, colorless liquid for vaporization, containing isoflurane USP as the sole active ingredient with no preservatives or stabilizing additives required. It is packaged in amber glass bottles of various volumes (e.g., 100 mL, 250 mL) for use exclusively with an isoflurane-specific, agent-calibrated vaporizer attached to an anesthesia machine.

Forane is a volatile halogenated ether general anesthetic (chemically, 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether). It is a clear, colorless, non-flammable liquid at room temperature with a pungent, ethereal odor, which vaporizes readily for administration by inhalation. It is chemically related to enflurane (an isomer) and desflurane.

Forane belongs to the class of volatile halogenated general anesthetics, used for induction and maintenance of general (surgical) anesthesia.

Pharmacodynamics

The precise molecular mechanism by which Isoflurane and other volatile anesthetics produce general anesthesia is not fully established; proposed mechanisms include modulation of ligand-gated ion channels (e.g., potentiation of inhibitory GABA-A and glycine receptors, inhibition of excitatory NMDA and nicotinic acetylcholine receptors) in the central nervous system, producing dose-dependent unconsciousness, amnesia, immobility to surgical stimulus, and some degree of muscle relaxation. It produces dose-dependent depression of respiration and cardiovascular function, and causes cerebral vasodilation.

Pharmacokinetics

• Absorption/Uptake: Administered by inhalation; uptake and elimination are governed by its blood-gas partition coefficient (relatively low, allowing reasonably rapid induction and emergence compared to older agents).
• Distribution: Distributes rapidly to highly perfused tissues (brain, heart) and more slowly to muscle and fat; crosses the placenta.
• Metabolism: Minimally metabolized (approximately 0.2% of absorbed dose) by the liver, mainly to trifluoroacetic acid and inorganic fluoride; this low metabolic rate contributes to a lower risk of organ toxicity compared with some older halogenated agents.
• Elimination: Predominantly eliminated unchanged via exhalation from the lungs.

Forane is administered exclusively by inhalation using an anesthesia machine fitted with a vaporizer specifically calibrated for Forane; vaporizers designed for other agents must never be used. Administration requires continuous monitoring of oxygenation, ventilation, circulation, and temperature, along with immediate availability of airway management and resuscitation equipment. Desiccated (dried-out) carbon dioxide absorbents in the anesthesia circuit should be avoided or replaced before use, as they can react with Forane to produce carbon monoxide.

Forane has clinically significant interactions with:

• Nitrous oxide and opioid analgesics: Reduce the minimum alveolar concentration (MAC) of Forane needed for anesthesia; doses must be adjusted accordingly to avoid overdose.
• Neuromuscular blocking agents (e.g., non-depolarizing muscle relaxants): Forane potentiates their effect; doses of neuromuscular blockers typically need to be reduced by approximately 25-40%.
• Epinephrine (adrenaline) and other sympathomimetics: Sensitizes the myocardium to catecholamines; doses of epinephrine above approximately 5 mcg/kg may provoke ventricular arrhythmias.
• Calcium channel blockers: May cause pronounced hypotension when combined with Forane's vasodilatory and myocardial depressant effects.
• Beta-blockers: May produce exaggerated cardiovascular (hypotensive/bradycardic) depression in combination with Forane.
• Monoamine oxidase inhibitors: May increase the risk of intraoperative hemodynamic instability.
• Succinylcholine: Co-administration increases the risk of triggering malignant hyperthermia (see Contraindications).

The anesthesia team reviews all concurrent medications before and during administration of Forane.

Because Forane is used only under continuous anesthesia monitoring, its effects are closely observed and managed by the care team. Common effects, particularly during induction and emergence, include:

• Agitation or restlessness (particularly on emergence)
• Coughing and breath-holding (induction, due to airway irritation)
• Nausea and vomiting (post-operative)
• Chills/shivering on emergence
• Laryngospasm (induction)

Serious but less common effects include dose-dependent hypotension, cardiac arrhythmias, and respiratory depression, all of which are actively managed intraoperatively. Rare but serious reactions include malignant hyperthermia, hepatic injury (sensitivity-type hepatitis, more strongly associated with older agents like halothane but reported with Forane), severe hyperkalemia (particularly in patients with underlying muscular dystrophies), and anaphylaxis (see Precautions and Warnings).

Pregnancy: Adequate and well-controlled studies of Forane in human pregnancy, including obstetric anesthesia, have not been established. Animal studies have shown embryo-fetal effects at higher/prolonged exposures. General anesthesia in pregnancy is generally reserved for situations where it is clearly needed (e.g., emergency or medically necessary surgery), and the decision to use Forane should be made by the obstetric and anesthesia team weighing potential benefit against potential risk to the fetus.

Lactation: Data on excretion of Forane into breast milk are limited; given its rapid pulmonary elimination, clinically significant transfer is considered unlikely, but a physician should be consulted regarding timing of breastfeeding resumption after anesthesia.

• Malignant hyperthermia: A life-threatening hypermetabolic crisis can be triggered by Forane, particularly in genetically susceptible individuals and especially with concurrent succinylcholine use; signs include unexplained rise in end-tidal CO2, muscle rigidity, tachycardia, and rapidly rising temperature. Treatment requires immediate discontinuation of the triggering agent and administration of intravenous dantrolene, along with supportive care.
• Perioperative hyperkalemia: Rare but life-threatening hyperkalemia with cardiac arrhythmias has occurred, particularly in pediatric patients with previously undiagnosed skeletal muscle myopathies (e.g., Duchenne muscular dystrophy); early and aggressive treatment is required if this occurs.
• Hepatic effects: Rare cases of hepatic dysfunction and hepatitis have been reported, particularly with repeated exposure to halogenated anesthetics within a short interval; a careful anesthetic history should be taken.
• Hypersensitivity reactions: Anaphylaxis has been reported.
• Respiratory and cardiovascular depression: Forane produces dose-dependent respiratory depression and hypotension; requires continuous monitoring and is not suitable for use outside a supervised anesthesia setting.
• QT interval prolongation: Has been reported rarely; use with caution and monitor cardiac rhythm in patients with, or at risk for, QT prolongation (e.g., Torsade de Pointes).
• Carbon monoxide formation: Desiccated carbon dioxide absorbents in the anesthesia circuit can react with Forane to generate carbon monoxide; absorbents should not be allowed to dry out and should be replaced when indicated.
• Pediatric neurotoxicity signal: Repeated or prolonged (generally over 3 hours) exposure to general anesthetics, including Forane, in young children and in the third trimester of pregnancy may affect brain development, based on animal studies; the anesthesia team weighs this against the necessity of the procedure.
• Hypovolemia: Use with particular caution in hypovolemic patients, as Forane can exacerbate hypotension.
• Not for self-administration: Forane must be administered only by trained anesthesia personnel with specialized vaporizer equipment and continuous monitoring; it is never a ward-level or self-administered medication.

Overdose or excessive depth of anesthesia with Forane presents as progressive cardiovascular and respiratory depression - severe hypotension, bradycardia or other arrhythmias, and respiratory depression or apnea. This is a medical emergency requiring immediate management by the anesthesia team: discontinuation of the anesthetic, securing and supporting the airway, ventilation with 100% oxygen, and cardiovascular support as needed. Because Forane is administered only under continuous monitoring in a hospital setting, this scenario is managed on-site by trained personnel; it is not an outpatient or home-management situation.

Store Forane at room temperature (below 30°C), tightly closed in its original amber glass container, away from light, open flame, and moisture. Keep out of reach of children. Use only with vaporizers and equipment specifically designed and calibrated for Forane.

Renal impairment: Forane undergoes minimal renal elimination of parent drug; inorganic fluoride, a minor metabolite, is renally cleared, but clinically significant nephrotoxicity from Forane at usual exposures is not established. Use with routine intraoperative monitoring.

Hepatic impairment: Forane undergoes minimal hepatic metabolism and is generally considered among the less hepatotoxic volatile agents, but caution and careful monitoring are warranted in patients with significant hepatic disease or a prior history of anesthetic-associated hepatic dysfunction (see Contraindications).

Elderly patients: Generally require lower minimum alveolar concentrations (MAC) than younger adults; doses are individualized accordingly, with attention to cardiovascular reserve.

Pediatric and geriatric use: See Pediatric Uses below.

Forane is used only for the duration of a surgical or diagnostic procedure requiring general anesthesia, from induction (or after induction with another agent) through maintenance, and is discontinued as the procedure concludes to allow emergence from anesthesia. It has no role in ongoing or repeated outpatient treatment; total duration of exposure during a single anesthetic is determined by the anesthesia provider based on the length and nature of the procedure.

Isoflurane is classified under: General anesthetics; Volatile/inhalational anesthetics; Halogenated ether anesthetics.

The exact mechanism of general anesthesia produced by Isoflurane is not completely understood. It is believed to act primarily within the central nervous system by enhancing inhibitory neurotransmission (potentiating GABA-A and glycine receptor-mediated chloride currents) and reducing excitatory neurotransmission (inhibiting NMDA-type glutamate receptors and neuronal nicotinic acetylcholine receptors), producing dose-dependent unconsciousness, amnesia, analgesia, and immobility in response to surgical stimulation, along with dose-dependent respiratory and cardiovascular depression (see Pharmacology for full detail).

Forane is used for induction and maintenance of general anesthesia in pediatric patients, including infants and children, but its pungent, ethereal odor commonly causes airway irritation, coughing, and breath-holding, making it less suitable than some other agents for inhalational (mask) induction in children; it is more commonly used for maintenance after induction with another agent. Pediatric patients with previously undiagnosed skeletal muscle myopathies (e.g., Duchenne muscular dystrophy) are at increased risk of rare but life-threatening perioperative rhabdomyolysis and hyperkalemia with Forane and other volatile anesthetics; a family history of anesthesia-related complications should be sought before use. Based on animal data, repeated or prolonged (generally over 3 hours) exposure to general anesthetics in children under 3 years of age may affect brain development; the anesthesia and surgical team weighs this concern against the necessity and urgency of the procedure, and single, medically necessary exposures are not typically avoided. Forane must be administered to pediatric patients only by personnel experienced in pediatric anesthesia, with continuous monitoring.